A Study of TAS1440 With ATRA in Subjects With r/r AML

Summary

This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent and in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid leukemia (AML) who have relapsed or are refractory (r/r) to prior treatment. The study duration is expected to be approximately 30 months.

Timeline

Start

2020-03-15

Primary completion

2024-02-12

Completion

2024-02-12

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible participants, and little likelihood of providing meaningful clinical benefit for the participants.”

Drugs

Indications